Enanta Pharmaceuticals, Inc
Enanta Pharmaceuticals is dedicated to creating important, novel medicines through innovative chemistry and scientific excellence. They have developed drugs for combination regimens that have cured over one million people with chronic hepatitis C virus infection. The company is committed to improving patients' lives and expanding into other disease areas. Enanta employs rigorous research and scientific excellence, with a focus on high unmet needs in disease treatment. They have a strong pipeline including treatments for hepatitis C, hepatitis B, respiratory syncytial virus (RSV), SARS-CoV-2, and immunology, supported by extensive publications and clinical trials. The company values innovation, scientific rigor, and patient impact.
Industries
Nr. of Employees
medium (51-250)
Enanta Pharmaceuticals, Inc
Patents
Products
Small-molecule combination therapies for chronic hepatitis C
Contributions to small-molecule combination regimens for chronic hepatitis C that progressed to marketed regimens with demonstrated curative outcomes.
Oral RSV non-fusion and L‑protein inhibitor candidates
Orally administered small-molecule candidates that inhibit respiratory syncytial virus replication via non-fusion and L‑protein mechanisms, advanced into early-phase and human challenge studies.
Oral 3CL protease inhibitor candidate for SARS-CoV-2
Lead oral 3CL protease inhibitor candidate designed to inhibit SARS-CoV-2 replication, progressed through preclinical and early clinical evaluation with regulatory engagement.
HBV core protein inhibitor program
Small-molecule HBV core inhibitor series developed to reduce viral biomarkers and advanced into clinical testing for chronic hepatitis B.
Farnesoid X receptor (FXR) agonist program for NASH
Development of FXR agonist small-molecule candidates evaluated in preclinical models and clinical studies for non-alcoholic steatohepatitis and related hepatic indications.
Small-molecule combination therapies for chronic hepatitis C
Contributions to small-molecule combination regimens for chronic hepatitis C that progressed to marketed regimens with demonstrated curative outcomes.
Oral RSV non-fusion and L‑protein inhibitor candidates
Orally administered small-molecule candidates that inhibit respiratory syncytial virus replication via non-fusion and L‑protein mechanisms, advanced into early-phase and human challenge studies.
Oral 3CL protease inhibitor candidate for SARS-CoV-2
Lead oral 3CL protease inhibitor candidate designed to inhibit SARS-CoV-2 replication, progressed through preclinical and early clinical evaluation with regulatory engagement.
HBV core protein inhibitor program
Small-molecule HBV core inhibitor series developed to reduce viral biomarkers and advanced into clinical testing for chronic hepatitis B.
Farnesoid X receptor (FXR) agonist program for NASH
Development of FXR agonist small-molecule candidates evaluated in preclinical models and clinical studies for non-alcoholic steatohepatitis and related hepatic indications.
Services
Establishing collaborations, licensing and partnership agreements to advance discovery programs and enable commercialization.
Design and conduct of clinical studies including Phase 1–3 trials, pediatric studies and controlled human challenge studies to evaluate candidate safety and efficacy.
Integrated preclinical services including high-throughput screening, biochemical and cell-based assays, DMPK/ADME studies, PK/PD analysis, tissue distribution and in vivo efficacy testing across multiple species.
Establishing collaborations, licensing and partnership agreements to advance discovery programs and enable commercialization.
Design and conduct of clinical studies including Phase 1–3 trials, pediatric studies and controlled human challenge studies to evaluate candidate safety and efficacy.
Integrated preclinical services including high-throughput screening, biochemical and cell-based assays, DMPK/ADME studies, PK/PD analysis, tissue distribution and in vivo efficacy testing across multiple species.
Expertise Areas
- Medicinal chemistry
- Antiviral small-molecule discovery
- Protease and polymerase inhibitor development
- Preclinical in vitro and in vivo pharmacology
Key Technologies
- Small-molecule discovery and lead optimization
- Protease inhibitor platforms
- Polymerase (RdRp/L-protein) and non-fusion inhibitor screening
- High-throughput biochemical and cell-based screening